Hematology Tablet Franchise in Ahmedabad

Eltrombopag Tablet Supplier in Mumbai

Platelet Booster Tablet Distributor in Delhi

Thrombopoietin Receptor Agonist Manufacturer in Bangalore

Thrombocytopenia Treatment Tablet Stockist in Hyderabad
Hematology Medicine Exporter in Chandigarh

Home/Products /eltrombopag-25mg-tablet

Eltrohype 25 Tablet

Composition : Eltrombopag (25mg) Tablet

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 2x7

Price : ₹0/-

Eltrombopag 25 mg Tablet is a thrombopoietin receptor agonist indicated for the treatment of chronic immune thrombocytopenia (ITP) and thrombocytopenia in patients with chronic hepatitis C. It helps stimulate platelet production and reduce the risk of bleeding complications.

The drug works by activating thrombopoietin receptors on bone marrow progenitor cells, leading to increased platelet formation. This targeted mechanism supports safe and controlled elevation of platelet counts under medical supervision.

Clinically, Eltrombopag 25 mg Tablet is prescribed in patients with low platelet counts who are unresponsive to conventional therapies, ensuring better disease management and improved treatment outcomes.

Due to its role in long-term hematological care and specialized treatment protocols, this therapy supports steady demand and repeat prescriptions, helping healthcare businesses expand their specialty medicine portfolio and serve patients requiring advanced platelet management solutions.

Read More

About the Product

Eltrombopag 25 mg Tablet is a thrombopoietin receptor agonist indicated for the treatment of chronic immune thrombocytopenia (ITP) and thrombocytopenia in patients with chronic hepatitis C. It helps stimulate platelet production and reduce the risk of bleeding complications.

The drug works by activating thrombopoietin receptors on bone marrow progenitor cells, leading to increased platelet formation. This targeted mechanism supports safe and controlled elevation of platelet counts under medical supervision.

Clinically, Eltrombopag 25 mg Tablet is prescribed in patients with low platelet counts who are unresponsive to conventional therapies, ensuring better disease management and improved treatment outcomes.

Due to its role in long-term hematological care and specialized treatment protocols, this therapy supports steady demand and repeat prescriptions, helping healthcare businesses expand their specialty medicine portfolio and serve patients requiring advanced platelet management solutions.

Common side effects may include headache, nausea, diarrhea, fatigue, and upper respiratory tract infections. Elevated liver enzymes and thromboembolic events may occur rarely.

Eltrohype 25 Tablet is indicated for the treatment of chronic immune thrombocytopenia (ITP) in patients who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. It is also used in thrombocytopenia associated with chronic hepatitis C and severe aplastic anemia as advised by a physician.

Use this medicine strictly under medical supervision. Regular monitoring of platelet count and liver function tests is required during therapy. Do not exceed the prescribed dose. Inform the doctor of any history of liver disease or blood clotting disorders.

Store below 25°C in a cool, dry place. Protect from light and moisture. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation